For research purposes only — These compounds aren't FDA approved. All data presented is from clinical trials for educational reference.
AOD-9604
Composition Peptide
Dosage
Quantity
Price
$44.99
Free shipping on orders $150+
60-day money-back guarantee
Secure checkout
Made in the USA
Certificate of Analysis
Batch verified lab data
99.93%
Purity
- Variant
- AOD-9604 5mg
- Lot #
- A0112
- Labeled
- 20mg
- Actual
- 22.56mg
- Tested
- Feb 4, 2026
Frequently Researched Together
View allResearch Purposes Snapshot
AOD-9604 is a synthetic fragment of human growth hormone (hGH 176–191) engineered to engage lipolytic signaling without the full anabolic / IGF-1 axis of intact hGH. Obesity development stopped after Phase 2b, but preclinical and early clinical archives remain widely cited for metabolic and cartilage models—educational only for this listing.
7×
β3-AR upregulation
Adipocyte reports describe marked β3-adrenergic receptor expression increases vs controls (Heffernan et al., 2001).
70%
Cartilage signal
Rabbit osteoarthritis model: ~70% cartilage thickness improvement in cited preclinical work (Kwon et al., 2015).
2.8 kg
Weight loss
OPTIONS Phase 2b narrative: ~2.8 kg mean loss at 1 mg daily over 12 weeks vs ~0.8 kg placebo (approximate).
100%
Glucose-neutral
Human trials report no meaningful fasting glucose excursions across tested doses (Stier et al., 2013).
0%
Anti-drug antibodies
Immunogenicity panels commonly report absence of neutralizing anti-AOD-9604 antibodies.
Development status
Where it stands
- Historical sponsor
- Metabolic Pharmaceuticals (trial-era)
- Primary indication tested
- Obesity (OPTIONS program)
- Phase 2b outcome
- Did not meet commercial efficacy bar
- Current framing
- Research compound / legacy dataset
Key mechanism
Why it differs from intact hGH
Full hGH elevates IGF-1, perturbs insulin sensitivity, and carries broad anabolic liability. AOD-9604 is positioned as a lipolytic-domain mimic that retains fat-oxidation biology while sparing carbohydrate metabolism and IGF-1 in human dosing ranges studied to date.
- Fat oxidation↑ similar to hGH in model systems
- IGF-1No change
- Blood glucoseNeutral
- Insulin sensitivityUnchanged
What research has shown
Human obesity trials plus preclinical cartilage work
Phase 2b OPTIONS (300+ subjects)
2.8 kg
Approximate mean loss — 1 mg daily × 12 weeks
Percent weight change (illustrative)
The 24-week Phase 2b program did not achieve sponsor efficacy hurdles for obesity commercialization, yet safety and tolerability narratives remained favorable—fueling continued niche research (joint models, fat oxidation).
Human + preclinical signals
AOD-9604 vs other weight-loss datapoints
- AOD-9604 (1 mg cohorts)~2.8% BW
- Lifestyle-only controls (trial narratives)~0.8% BW
- Orlistat (meta-analytic comparators)~2.9% BW
Orlistat figures derive from separate meta-analyses—not a randomized head-to-head against AOD-9604.
Beyond weight loss
Other research threads
Joint repair
Cartilage-centric OA models (Kwon et al., 2015).
0 glucose Δ
Fasting glucose stable (Stier et al., 2013).
7× β3-AR
Adipocyte receptor program (Heffernan et al., 2001).
Placebo-like AE
Six-trial tolerability narrative (JOFEM-style reviews).
Joint health
Cartilage regeneration potential
Preclinical OA work describes thickness gains (~70%) with intra-articular schedules; ultrasound-guided delivery plus hyaluronic acid co-administration is discussed as synergistic in specialty case series.
- Example regimen cited: ~0.25 mg weekly × 4–7 weeks (model-dependent)
Ann Clin Lab Sci (2015): combination ultrasound-guided IA protocols reported superior structural scores vs monotherapy arms in archived data.
Metabolism
Selective fat oxidation
Adipocyte work ties AOD-9604 to increased lipolysis / oxidation without parallel muscle catabolism or glycemic shifts in the same experimental frames.
Heffernan et al., 2001
Safety archive
Human exposure
600+
Patients across six clinical trials (review summaries)
Safety profile from research
Pooled trial language
Reviewed human programs describe placebo-comparable AE rates with mild injection-site complaints dominating; metabolic labs remain boringly stable versus hGH comparators.
Frequently cited mild events
Injection site
MildHeadache
MildFatigue
MildNausea
MildNo classic hGH liabilities (trial narratives)
- Fasting glucose unchanged
- Insulin sensitivity unchanged
- IGF-1 unchanged
- No anti-AOD-9604 antibody signal
Discontinuation
- 0.25 mg<5%
- 0.5 mg<5%
- 1 mg<5%
Similar to placebo; few serious AEs attributed to drug; many withdrawals unrelated per CSR-style summaries.
Storage handling reference
Peptide handling
Cold
Lyophilized: store per COA.
Reconstitution
Sterile technique; verify route.
Light
Protect from UV during prep.
Traceability
Log batch and concentration.
Researcher notes
- 600+ unique exposures across six sponsor trials underpin the tolerability story—still not a post-market surveillance database.
- Public reviews rarely describe tachyphylaxis, but long-term recreational use is unstudied.
- Safety messaging holds for 24-week windows in archives; beyond that is extrapolation.
- WADA bans the parent fragment class—assume testing positives even if labeled “research only.”
Important Research Notice
Not for human consumption. This product and all products are sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.
All clinical trial data and research findings presented on this page are sourced from journals and official publications but should be fact checked. They are provided for educational reference only and should not be interpreted as medical advice or product claims.
By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations and you do not intend to use it for human consumption.